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Background: The level of asymptomatic infection with SARS-CoV-2 could be substantial and among health care
workers (HCWs) a source of continuing transmission of the virus to patients and co-workers.
Objectives: Measure the period prevalence of SARS-CoV-2 PCR positivity and seroprevalence of SARS-CoV-2 IgG
antibodies among a random sample of asymptomatic health system hospital-based health care workers (HCWs)
6½ -15½ weeks after 4/5/2020, the peak of the first surge of COVID-19 admissions.
Results: Of 524 eligible and consented participants from four metropolitan hospitals, nasopharyngeal swabs were
obtained from 439 (83.8 %) and blood from 374 (71.4 %). Using PCR nucleic acid-based amplification (NAAT)
methods, the period prevalence of SARS-CoV-2 infection was 0.23 % (95 % confidence interval (CI) 0.01 %–1.28
%; 1/439) from 5/21/20− 7/16/20. The seroprevalence of SARS-CoV-2 IgG antibodies from June 17-July 24,
2020 was 2.41 % (95 % CI 1.27 %–4.51 %; 9/374). Those who were reactive were younger (median age 36
versus 44 years; p = 0.050), and those with self-reported Hispanic/Latino ethnicity had a higher seroprevalence
(2/12 = 16.7 % versus 7/352 = 2.0 %; p = 0.051). There were no significant differences by sex, race, residence,
hospital, unit or job type. The one employee who was found to be PCR test positive in this study was also reactive
for IgG antibodies, tested 27 days later.
Conclusions: The period prevalence of PCR positivity to SARS-CoV-2 and IgG seroprevalence was unexpectedly
low in asymptomatic HCWs after a peak in COVID-19 admissions and the establishment of state and institutional
infection control policies, suggesting that routine screening tests while community prevalence is relatively low
would produce a minimal yield.

1. Background

Health System (HFHS) had a peak number of COVID-19 inpatients (n =
603) in its four metropolitan Detroit hospitals on 4/5/20. Stringent
infection control policies were put in place as the pandemic progressed,
including a universal masking policy on 4/7/20 [4]. The number of
inpatients dropped markedly until reaching lower rates in May 2020
(average COVID-19 bed census 68.4; 95 % confidence interval (CI)
64.5–72.4). A recent meta-analysis of COVID-19 screening studies
among asymptomatic HCWs across the world yielded an estimated
pooled prevalence of 5% (95 % confidence interval (CI) of 1–13), but the
analysis included time periods of both peak and low community disease
activity [5].

As the novel SARS COV-2 virus began its sweep across the world in
late 2019, health care workers (HCWs) were at risk of COVID-19
morbidity and mortality through work and community exposure as
well as being potential transmission sources of nosocomial infection for
patients and co-workers [1,2]. Metropolitan Detroit, Michigan devel
oped as a “hot spot” in March 2020, with the first two cases in the state
confirmed on 3/10/20, statewide polices on social distancing and
stay-in-place for non-essential workers mandated on 3/23/20, and the
highest number of cases reached in early April 2020 [3]. Henry Ford
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Fig. 1. Disposition of Study Recruitment and Enrollment.

2. Objectives

which was approved for SARS-CoV-2 testing under the FDA Emergency
Use Authorization (EUA). The assay detected dual SARS-CoV-2 targets,
the NSP-2 and the N gene. Testing for IgG was performed on serum
samples using the Access SARS-CoV-2 IgG antibodies assay (Beckman
Coulter, Chaska, MN).
Non-parametric tests (Fisher’s exact test and Kruskal-Wallis test),
were used to assess differences between participants and nonparticipants and populations with positive versus negative test results.
Prevalence estimates and 95 % CIs were calculated [6].
All study processes and procedures were approved by the HFHS
Institutional Review Board (IRB #13,878) and electronic informed
consents obtained.

To address concerns about hospital-based transmission, a study was
designed to determine whether the prevalence of detectable SARS-CoV2 among asymptomatic HCWs, during a post-surge period and as regular
hospital activities resumed, justified the need for routine screening.
After the study started, a serology test became available, which was also
offered to participants to evaluate the seroprevalence of IgG antibodies
to the virus.
3. Study design
A list of employees actively working at the HFHS academic hospital
and its 3 Detroit-area community hospitals in patient-facing clinical
areas was created that included names, occupation, work location, email
and phone number. A random sample was selected and invited to un
dergo testing for SARS-CoV-2 through the collection of nasopharyngeal
(NP) swabs. Starting on 5/27/20, following a pilot study that began on
5/20/20, recruitment emails were sent in batches, followed by reminder
emails and repeated phone contacts. Employees with any history of a
COVID-19 diagnosis were ineligible. As of 6/15/20, the SARS-CoV-2 IgG
antibodies test was also offered to new participants and those who had
already provided NP samples.
The NP swabs were collected in saline transport vials and tested for
SARS-CoV-2 using real-time reverse-transcriptase RT-PCR NAAT on the
NeumoDx 288 platform (NeumoDx Molecular Systems, Ann Arbor, MI)

4. Results
4.1. Study population
After initial exclusions, our final sampling frame included 11,213
individuals (Fig. 1).
A sample of 72 HCWs was selected for the pilot study followed by a
random sample of 2,500. Of these, 1,130 could not be contacted or were
determined to be ineligible. Of the remaining 1,442, 1,002 were con
tacted but did not enroll, while 440 (31 %) consented and received at
least one test. Statistically significant differences were found by hospital
of employment and job function between those eligible and consented (n
= 524), those not successfully contacted (n = 1,065), and those
2
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Table 1
Characteristics of HCWs by IgG reactivity.

Age at Consent
Sex:
Female
Male
Race:
White
Black
Other
Refused/Missing
Hispanic/Latino Ancestry:
Yes
No
Refused/Missing
Middle Eastern Ancestry:
Yes
No
Refused/Missing
Lives within Detroit City Limits:
No
Yes
Work Location:
Henry Ford Hospital
West Bloomfield Community
Hospital
Macomb Community Hospital
Wyandotte Community
Hospital
Job Function:
Nursing
Physicians
Leadership/Management
Admin Support/Business
Allied
Other
Where do you spend the majority
of your work day?:
ED
ICU
COVID-19 Care or Testing
Area
Inpatient Unit
Outpatient Clinic
Other
Have you been exposed to
anyone diagnosed with
COVID-19 confirmed by
laboratory testing?:
No
Yes
Do you live with anyone who
was diagnosed with COVID-19
confirmed by laboratory
testing?:
No
Yes
On a typical day, how many
other people live in your home
(Not including yourself)?

Table 1 (continued )

NonReactive
Reactive
N = 365
N=9
N (Row %) or Median [Q1;
Q3]

pvaluea

N

44.0
[34.8;55.0]

36.0
[29.8;42.5]

0.050

364

273 (97.8
%)
91 (96.8 %)

6 (2.15 %)

0.697

373

282 (97.6
%)
35 (97.2 %)
45 (97.8 %)
3 (100 %)

7 (2.42 %)

10 (83.3 %)
345 (98.0
%)
10 (100 %)

2 (16.7 %)
7 (1.99 %)

30 (100 %)
325 (97.3
%)
10 (100 %)

0 (0.00 %)
9 (2.69 %)

338 (97.4
%)
26 (100 %)

9 (2.59 %)

178 (97.8
%)
83 (96.5 %)

4 (2.20 %)

57 (96.6 %)
47 (100 %)

2 (3.39 %)
0 (0.00 %)

136 (96.5
%)
54 (98.2 %)
30 (93.8 %)
26 (100 %)
85 (100 %)
34 (97.1 %)

5 (3.55 %)

12 (100 %)
29 (100 %)
10 (100 %)

0 (0.00 %)
0 (0.00 %)
0 (0.00 %)

86 (96.6 %)
46 (97.9 %)
181 (97.3
%)

3 (3.37 %)
1 (2.13 %)
5 (2.69 %)

107 (98.2
%)
258 (97.4
%)

2 (1.83 %)

360 (97.6
%)
4 (100 %)
2.00
[1.00;3.00]

9 (2.44 %)

3 (3.19 %)

1 (2.78 %)
1 (2.17 %)
0 (0.00 %)

0 (0.00 %)

0 (0.00 %)

0 (0.00 %)

1.000

NonReactive
Reactive
N = 365
N=9
N (Row %) or Median [Q1;
Q3]
Do you have direct contact with
patients?:
No
Yes
Do you work in an area
categorized as direct COVID19 Care?:
No

374

Yes

0.051

374

1.000

374

1.000

373

0.643

374

Do you potentially come into
contact with COVID-19
contaminated items or enter
rooms where COVID-19
patients are bedded?:
No
Yes
Month of Antibody Testing:
June
July

1 (1.82 %)
2 (6.25 %)
0 (0.00 %)
0 (0.00 %)
1 (2.86 %)

374

0.972

373

187 (97.4
%)
174 (97.8
%)

5 (2.60 %)

118 (99.2
%)
246 (96.9
%)

1 (0.84 %)

126 (98.4
%)
230 (97.0
%)

2 (1.56 %)

0.693

371

1.000

370

0.282

373

0.503

365

4 (2.25 %)

8 (3.15 %)

7 (2.95 %)

contacted who did not participate (n = 918), both p < 0.001. Nurses
were the most difficult to contact, and managers and allied health staff
were more likely to participate, while facility/security staff were less
likely. Males were less likely to participate than females (p = 0.059). A
total of 373 had both tests completed (average of 18 days between NP
swab and blood draw); 66 had only an NP swab collected and one
participant only had a serology test.
4.2. PCR testing
There was one HCW with a positive NAAT test of 439 tested from 5/
21/20− 7/16/20. The period prevalence of positive NAAT tests among
asymptomatic HCWs was 0.23 % (95 % CI 0.01 %–1.28 %).
4.3. Serology testing

1.000

374

1.000

373

0.734

372

Table 1 presents the characteristics of the 374 participants who
provided blood samples from 6/17/20− 7/24/20. Nine HCWs were
reactive, corresponding to a seroprevalence of IgG to SARS-CoV-2 of
2.41 % (95 % CI 1.27 %–4.51 %). Those who were reactive were
younger (median age 36 years versus 44 years; p = 0.050), and those
self-identified as Hispanic had higher reactivity (16.7 % versus 1.99 %; p
= 0.051). There were no differences by sex, race, Middle Eastern
ancestry, city residence, hospital of employment, job, or direct contact
with COVID-19 patients.
The specimen of the one participant who had a positive NAAT test
was collected in the end of May 2020, followed by a blood draw for an
IgG antibodies test 27 days later, which was also positive. The SARS antiIgG assay we used demonstrated 100 % PPV at 14 days post-PCR at our
overall PCR positive rate of 5.9 % during assay validation (data not
shown). The low prevalence of PCR positivity in our asymptomatic HCW
population of 0.23 % would reduce the PPV to approximately 22 %, with
an NPV of 100 %.

7 (2.64 %)

0 (0.00 %)
2.00
[1.00;3.00]

1 (1.33 %)
8 (2.70 %)

N

a
Chi-squared or Fisher’s exact test when the expected frequencies is less than
5 in some cells for categorical covariates; Kruskal-Wallis test for continuous
covariates.

3 (3.49 %)

0.258

74 (98.7 %)
288 (97.3
%)

pvaluea

3
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Table 2
Studies of SARS-CoV-2 detection by RT-PCR and IgG antibody seroprevalence among asymptomatic HCWs.
First Author,
Publication Date

Location

Setting

N of
asymptomatics
tested

Period

Positivity
(%)

Antibody Prevalence
(%)

Rivett L [2]
(5/2020)
Korth J [7]
(5/2020)

Cambridge, UK

Teaching hospital; screening asymptomatic HCWs
from high risk areas; low community prevalence
University hospital, 2− 3 weeks pre-peak, HCW with
varying levels of contact, detected 5 asymptomatic
cases but 4 reported previous symptoms

1032

4/6/20− 4/24/
20
3/25/20− 4/
21/2020

0.6*

NA

NA

1.6 (0.32 if exclude
those with previous
symptoms)

Essen, Germany

Treibel TA (5/
2020) [8]

London, UK

Martin C [9]
(6/2020)

Brussels,
Belgium

Al-zoubi NA [10]
(6/2020)

Irbid, Jordan

Lahner E [11]
(6/2020)

Rome, Italy

Garcia-Basteiro
AL [12]
(7/2020)

Barcelona, Spain

Brant-Zawadzki M
[13] (7/2020)

Orange County
CA, USA

Vahidy FS [14]
(7/2020)
Blairon L [15]
(8/2020)
Grant JJ [16]
(9/2020)
Martin C [17]
(11/2020)
Martin C [18]
(12/2020)
Varona JF [19]
(1/2021)
Kantele A [20]
(1− 2/2021)
Piccoli L [21]
(2/2021)

Houston, TX,
USA
Brussels,
Belgium

Trieu, M [22]
2/2021

Consortium of hospitals following a cohort of
asymptomatic HCW volunteers
Tertiary hospital, cohort of staff working in units
with COVID patients or ED to be followed
longitudinally; peak admits 3/31/20
University hospital, all staff assigned; peak admits
on 5/1/20
Teaching hospital; calculated asymptomatic %; low
incidence region
Tertiary hospital; cohort of random sample of HCWs
at baseline to be followed; epidemic rapidly growing
in community
Regional hospital, all employees invited to
participate, to be followed; low community
prevalence
Academic medical center and 7 affiliated community
hospitals

316

400

3/23− 3/29
(baseline)
3/30− 4/5
4/6− 4/12
4/13− 4/19
4/20− 4/26

270

4− 15-20 to
~5− 3-20

370
2115 NP
1084 Serology

NA

0.7

4.8

0

NA

0.9

0.7

3/28/20− 4/9/
20

0.8

3.0**

2920

May-June 2020

NA

0.86

3.9

NA

0.0***

7.1

NA

14 %

NA

6.6

0.0

NA

0.4

4.7

2.8

3.0

NA

2.4

1.3

3.0

2787
630

London,UK

Health care system, self-referred HCWs

973

Leicester,UK

University hospitals

7828

Leicester,UK

University hospitals, low community prevalence

1150

Spain

17 hospitals, all employees invited

5589

Helsinki, Finland

Secondary/tertiary university hospital; samples of
selected wards/units

1095

5 hospitals, all employees invited

1089

Hospitals/EDs testing and treating COVID-19
patients, cohort of asymptomatic HCWs followed
through first pandemic wave

607

Bergen, Norway

4.9
1.5
1.5
1.1

368

Public hospital network, peak on 4/10/20

Canton of Ticino,
Switzerland

4/22/20-4/29/
20
NP: 3/18/
20− 4/27/20
Serology:4/
0720− 4/27/20

7.1

3/11/20− 4/
19/20
5/25/20− 6/
19/20
5/15/2020− 6/
5/2020
5/29/2020− 7/
13/2020
7/20/20− 8/
14/2020
4/15/2020− 6/
30/2020
4/22/20− 5/
15/20
4/16/2020− 4/
30/2020
4/2020− 5/
2020

*

Self collected nose and throat swab.
Either IgA, IgM or IgG reactive.
***
7 were positive but uncertain whether these individuals previously symptomatic or not; all cultured and negative.
**

5. Discussion

respectively.
Like others, we found a higher prevalence in younger HCWs. [11,13]
One other US study of both symptomatic and asymptomatic HCWs re
ported a higher prevalence of SARS-CoV-2 IgG antibodies among His
panic/Latinos employees, [13] perhaps reflecting the higher community
COVID-19 incidence in this group.[23,24] Direct COVID-19 patient
exposure was not associated with prevalence; that and an infection
prevalence similar to the community implies the effectiveness of infec
tion control policies. Some have reported increased detection of SARS
antibodies by combining IgM and IgG results from separate assays [25].
In similar fashion, using a dual serology algorithmic approach may in
crease detection capability. At the time of this study, the IgG assay used
was the only COVID-19 antibody assay in our laboratory. Since then, we
have added testing for total SARS antibodies (IgG + IgM) using the
Cobas SARS-CoV-2 Total antibodies assay and automated
high-throughput e801 analyzers (Roche Diagnostics, Indianapolis, IN).
Early findings in a study of initial and sustained antibodies to COVID-19
have demonstrated 98.6 % agreement of the two serologic assays,
making a dual testing approach of minimal value in our setting (data not

The period prevalence study of SARS-CoV-2 detection and IgG
seroprevalence among a random sample of HCWs in an academic hos
pital and three affiliated community hospitals 45–109 days post the peak
number of COVID-19 admissions demonstrated unexpectedly low esti
mates. However, a literature review [2,7–22] indicates that most studies
of asymptomatic HCWs show similarly low estimates (Table 2).
Consideration of the timing of testing related to the phase of the
epidemic locally is critical, [9] as is the timing related to the ready
availability and compliant use of personal protective equipment (PPE)
[1]. The community prevalence during the study period was also low,
with a proportion of positive tests for SARS-CoV-2 for the entire state of
Michigan of 0.6 % (95 % CI 0.59− 0.61) [3], commensurate with that of
the HCW’s estimate in this study. Also, over the same dates as this study,
the average daily COVID-19 inpatient census was 26.5 (95 % CI
24.3–28.7) and the prevalence estimates for asymptomatic patients
being screened for COVID-19 prior to undergoing surgeries, non-surgical
procedures, or delivering a baby at HFHS were 0.9 %, 0.3 % and 1.5 %,
4
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shown).
Limitations of this study included a longer time to enroll participants
than expected, stretching out the period of prevalence, an inability to
contact many of those selected to participate and a higher than expected
number of refusals. We suspect that many of those who could not be
contacted were passive refusers. At the time of the study, it is probable
that HCWs felt less fearful of being infected, as well as fatigued from
research requests and COVID-related concerns. The low prevalence of
COVID-19 in our asymptomatic HCWs also means that some of the
observed serology positives might in fact be false positive results.
Strengths of the study were the exclusion of individuals with any pre
vious COVID-19 symptoms, diagnoses or positive tests, the use of CLIA
certified and FDA approved diagnostic tests, and the random sampling
design deployed in a large diverse health care workforce typical of other
US metropolitan hospitals.
These results demonstrate that the prevalence of COVID among
asymptomatic HCW’s after a local pandemic surge and after imple
mentation of COVID protection policies was similar or even lower to that
seen in the community. These results support others recommending that
at times of low community prevalence of SARS CoV-2, and given the
need to conserve testing supplies and reagents to maintain a reserve
capacity along with the high potential for false-positive tests; it is not
effective to routinely screen asymptomatic HCWs as long as COVID-19
protection policies are in place [18,26,27].
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S.A. Gómez-Ochoa, O.H. Franco, L.Z. Rojas, et al., COVID-19 in health-care
workers: a living systematic review and meta-analysis of prevalence, risk factors,
clinical characteristics, and outcomes, Am. J. Epidemiol. 190 (January (1)) (2021)
161–175, https://doi.org/10.1093/aje/kwaa191.
A. Agresti, B. Coull, Approximate is better than “exact” for interval estimation of
binomial proportions, Am. Stat. 52 (2) (1998) 119–126.
J. Korth, B. Wilde, S. Dolff, et al., SARS-CoV-2-specific antibody detection in
healthcare workers in Germany with direct contact to COVID-19 patients, J. Clin.
Virol. 128 (July) (2020), 104437, https://doi.org/10.1016/j.jcv.2020.104437.
T.A. Treibel, C. Manisty, M. Burton, et al., COVID-19: PCR screening of
asymptomatic health-care workers at London hospital, Lancet 395 (May (10237))
(2020) 1608–1610, https://doi.org/10.1016/s0140-6736(20)31100-4.
C. Martin, I. Montesinos, N. Dauby, et al., Dynamics of SARS-CoV-2 RT-PCR
positivity and seroprevalence among high-risk healthcare workers and hospital
staff, J. Hosp. Infect. 106 (September (1)) (2020) 102–106, https://doi.org/
10.1016/j.jhin.2020.06.028.
N.A. Al-Zoubi, B.R. Obeidat, M.A. Al-Ghazo, et al., Prevalence of positive COVID19 among asymptomatic health care workers who care patients infected with the
novel coronavirus: a retrospective study, Ann. Med. Surg. (Lond) 57 (September)
(2020) 14–16, https://doi.org/10.1016/j.amsu.2020.06.038.
E. Lahner, E. Dilaghi, C. Prestigiacomo, et al., Prevalence of Sars-Cov-2 infection in
health workers (HWs) and diagnostic test performance: the experience of a
teaching hospital in Central Italy, Int. J. Environ. Res. Public Health 17 (June (12))
(2020), https://doi.org/10.3390/ijerph17124417.
A.L. Garcia-Basteiro, G. Moncunill, M. Tortajada, et al., Seroprevalence of
antibodies against SARS-CoV-2 among health care workers in a large Spanish
reference hospital, Nat. Commun. 11 (July (1)) (2020) 3500, https://doi.org/
10.1038/s41467-020-17318-x.
M. Brant-Zawadzki, D. Fridman, P. Robinson, et al., SARS-CoV-2 Antibody
Prevalence in Health Care Workers: Preliminary Report of a Single Center Study,
2020, https://doi.org/10.1101/2020.07.20.20158329 medRxiv 2020.
07.20.20158329.
F.S. Vahidy, D.W. Bernard, M.L. Boom, et al., Prevalence of SARS-CoV-2 infection
among asymptomatic health care workers in the greater Houston, Texas, area,
JAMA Netw Open 3 (July (7)) (2020), https://doi.org/10.1001/
jamanetworkopen.2020.16451 e2016451.
L. Blairon, S. Mokrane, A. Wilmet, et al., Large-scale, molecular and serological
SARS-CoV-2 screening of healthcare workers in a 4-site public hospital in Belgium
after COVID-19 outbreak, J. Infect. 31 (July) (2020), https://doi.org/10.1016/j.
jinf.2020.07.033.
J.J. Grant, S.M.S. Wilmore, N.S. McCann, et al., Seroprevalence of SARS-CoV-2
antibodies in healthcare workers at a London NHS Trust, Infect. Control Hosp.
Epidemiol. 42 (February (2)) (2021) 212–214, https://doi.org/10.1017/
ice.2020.402.
C.A. Martin, P. Patel, C. Goss, et al., Demographic and occupational determinants
of anti-SARS-CoV-2 IgG seropositivity in hospital staff, J. Public Health Oxf. (Oxf)
(November) (2020) 16, https://doi.org/10.1093/pubmed/fdaa199.
C.A. Martin, D.R. Jenkins, P. Patel, et al., No cases of asymptomatic SARS-CoV-2
infection among healthcare staff in a city under lockdown restrictions: lessons to
inform’ Operation Moonshot’, J. Public Health Oxf. (Oxf) 26 (December) (2020)
https://doi.org/10.1093/pubmed/fdaa237.
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